Clinical Trial Update: Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients [Phase 1]

View source ↗

Summary

Phase 1 clinical trial completed evaluating DONQ52 in patients with Celiac Disease, assessing safety, tolerability, pharmacokinetics, and biomarkers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Celiac Disease

Drugs mentioned

• DONQ52

Snippet

Sponsor: Chugai Pharmaceutical | Conditions: Celiac Disease | Phase 1 | Status: COMPLETED